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Abstract 
Protein synthesis in living cells requires functional ribosomes which are composed of ribosomal proteins and 
ribosomal RNA (rRNA) molecules. rRNA is transcribed from tandemly repeated ribosomal DNA (rDNA) which 
is organised into a nuclear compartment termed the nucleolus in S-phase cells. It is essential that rDNA 
transcription is properly regulated in order to meet the cell's requirements for ribosomes and hence protein 
synthesis without wasting metabolic energy. In the last twenty years many proteins involved in regulating this 
process have been identified, suggesting that most organisms contain multiple protein complexes that regulate 
rDNA packaging and transcription. Importantly, it has become clear that errors in the function of these proteins 
can permit aberrant cellular growth, including in several classes of cancer. In this review, I discuss the history of 
how protein complexes such as the Nucleolar Remodelling Complex (NoRC) were discovered, using examples 
from humans and from model research organisms from different biological groups. I will discuss recent 
discoveries of the critical roles of rDNA-binding complexes in nucleolar assembly, the widespread occurrence of 
regulatory non-coding RNAs which interact with these complexes, and the pathways which regulate rDNA 
transcription in response to cellular energy status. Finally, I will review the growing evidence that misregulation 
of rDNA transcription not only allows the growth of cancerous cells, but can trigger oncogenesis itself. 
 
Introduction 
All living cells have an essential requirement to 
transcribe rRNA genes (rDNA) to produce rRNA 
for use in ribosome synthesis. Ribosome production 
is necessary to support translation of mRNA and 
consumes a significant proportion of the energy 
available to a typical living cell. rDNA 
transcription, which is performed in eukaryotes by 
RNA polymerase I, must be correctly regulated in 
order to ensure that the cellular requirement for 
ribosomal subunits is met. Studies in many groups 
of organisms have revealed the existence of 
multiple interacting pathways which ensure this 
regulation by up- or down-regulate total rRNA 
synthesis via activation or silencing of rDNA, 
respectively. It has also become clear that 
dysregulation of these pathways is associated with 
many pathologies, and in mammals is associated 
with, and often prognostic for, the occurrence of 
cancer. Control of transcription at rDNA has also 
been used as a paradigm for understanding 
eukaryotic gene expression in general. 
In this deep insight, key mechanisms that determine 
how rDNA transcription is controlled will be 
discussed. There is a particular focus on the 
pathways which act in mammalian cells, including 
those which have been implicated in 
tumourigenesis. However, reference is also made to 
some of the many insights into rDNA regulation 
revealed in other model biological systems, such as 
mutagenesis screens for loss of rDNA silencing in 
yeast, and some of the many epigenetic aspects of 
rDNA regulation discovered in hybrid plants of the 
Arabidopsis genus. As rRNA synthesis, the 
organisation of rDNA into nucleoli and the 
subsequent formation of ribosomes are all highly 
complex topics, this account will necessarily deal 
Mechanisms of rDNA silencing and the Nucleolar Remodelling Complex (NoRC) McKeown PC 
 
 
 
 
 
Atlas Genet Cytogenet Oncol Haematol. 2014; 18(10) 764 
only with certain key discoveries, together with 
some highlights of the recent literature. The reader 
will be referred to many excellent reviews from the 
last few years for further details where appropriate. 
In terms of organisation, this deep insight will 
begin with a general discussion of how RNA 
polymerase I acts to generate nascent rRNA 
molecules as precursors to ribosome biosynthesis, 
before turning to how this process is controlled. I 
will discuss the characteristics of rDNA regulation 
networks with particular biological or medical 
significance from different systems, before turning 
to aspects of how rDNA transcription has been 
linked to cancer. 
a) the mammalian NoRC complex and other 
complexes which interact with or oppose its 
activity;  
b) the links between rRDNA transcription and 
cellular energy status;  
c) other multi-protein complexes in plants and yeast 
which shed light on other aspects of rRNA 
transcription control;  
d) misregulation of rDNA regulation complexes 
and their links with cancer and other pathologies. 
rDNA chromatin and the 
organisation of the nucleolus 
Ribosomal RNA (rRNA) synthesis occurs in the 
nucleolus which assembles during the packaging 
and transcription of ribosomal DNA. In the 
nucleolus, tandemly repeated 45S ribosomal RNA 
genes (or rDNA) are transcribed to form 45S 
nascent pre-rRNA (Ballal et al., 1977). Each pre-
rRNA is cleaved and processed to form the 18S, 
5.8S and 25S rRNA molecules which are essential 
for the formation of ribosomes (Shaw and Jordan, 
1995). The nucleolus is not bound by any 
membrane but self-assembles during the processes 
of rRNA transcription and subsequent processing 
(Mélèse and Xue, 1995). Nucleoli are stable enough 
to be extracted from culture cells (Andersen et al., 
2002; McKeown et al., 2008) and studies in plants 
and animals have used mass spectrometry to 
identify proteins involved in the production of 
rRNA (Andersen et al., 2002; Pendle et al., 2005). 
Such studies have suggested that in many 
organisms nucleoli have also acquired additional 
cellular functions in stress response, splicing and 
small RNA biosynthesis (Pendle et al., 2005; Raška 
et al., 2006; Boisvert et al., 2007; Boulon et al., 
2010), although these will not be considered further 
here. 
In most eukaryotes, the rDNA locus consists of 
several hundred tandemly repeated rRNA genes, 
separated by linker regions. These are located at 
one or more large loci, which are also termed 
nucleolar organizing regions (NORs). The tandem 
repetition of rRNA genes is necessary as at least 
20-40 rRNA genes are required to meet the 
production levels of rRNA in a typical dividing cell 
(Sollner-Webb et al., 1985). Furthermore, most 
eukaryotes contain many more rRNA genes than 
this (usually in the range of 50-500) and under most 
conditions, only a subset of the total are actively 
transcribed while the others are silenced by a 
dosage-control mechanism (Dammann et al., 1993; 
Russell and Zomerdijk, 2005). A consequence of 
this is that rRNA synthesis can be up- or down-
regulated either by varying the number of active 
genes or by altering the transcription rate per gene, 
although the relative importance of these two 
pathways may vary between organisms (Dammann 
et al., 1993; French et al., 2003). Both processes are 
controlled by cellular signalling pathways of some 
complexity (Schmelzle and Hall, 2000; Stefanovsky 
et al., 2001; Grummt, 2003; Kim et al., 2003; Moss, 
2004).  
The inactive rRNA genes are maintained in a 
transcriptionally silent, inactive state which requires 
the interaction of many cellular processes (McStay 
and Grummt, 2008). This silencing ensures that the 
cell's energy is not expended on unnecessary rRNA 
synthesis, that rRNA genes which have 
accumulated mutations or become pseudogenic are 
not transcribed, and that the activity of other RNA 
polymerases within the rDNA is prevented 
(Dammann et al., 1993). As we will see, preventing 
aberrant rRNA transcription may also be an 
important barrier to tumour formation in mammals, 
and failure to repress aberrant may trigger 
oncogenesis under some circumstances. Finally, 
classic studies demonstrated that the cells of hybrid 
organisms generally silence the entire rDNA 
inherited from one parental species and activate that 
from the other (Navashin, 1934). This phenomenon 
is now known as nucleolar dominance and has been 
used to illustrate many of the pathways that regulate 
rDNA activity. 
A key issue for understanding rRNA transcription 
is therefore to understand the mechanistic basis of 
the switch between transcriptionally active and 
transcriptionally repressed rDNA. It was shown 
several decades ago that rDNA exists in two 
distinct conformations (that is, physical states 
within the nucleus), and that these can be stably 
inherited through mitosis (Conconi et al., 1989; 
Birch and Zomerdijk, 2008). The two forms of 
rDNA correspond to rRNA genes which are 
organised into different forms of chromatin, the 
DNA-protein superstructure into which DNA is 
'packaged' following binding by histone octamers 
(Prior et al., 1983).  
The two forms of rDNA chromatin can be 
distinguished on the basis of their differential 
accessibility to the DNA-crosslinking drug, 
psoralen.  
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Figure 1. Generalized model for the three chromatin states in which eukaryote rRNA genes may form. A) constitutively 
silent rDNA repeats organised into heterochromatin; B) rDNA repeats organised into euchromatin and actively transcribed by 
RNA Pol I (shown as a schematic core polymerase core and transcription factor; see text for details); C) 'poised' rDNA 
accessible to transcription machinery but not actively transcribed. 
 
One form has a highly compact psoralen-
inaccessible organisation corresponding to densely-
staining heterochromatin, and which is expected to 
be refractory to rRNA gene transcription.  
The other is a more dispersed, psoralen-accessible 
form which corresponds to the lightly-stained 
euchromatin and is expected to be permissive for 
transcription (Conconi et al., 1989; Dammann et al., 
1993). This suggests a basic conceptual model in 
which the activation level of rRNA genes depends 
upon a switch between two different chromatin 
states, which either repress transcription by Pol I or 
induce it, respectively. This also corresponds with 
electron microscopy investigations which confirm 
that rDNA can be present in one of two forms 
within the cell, one of which is indeed densely 
compacted in the manner of heterochromatin, while 
the second is less dense in the manner of 
euchromatin. 
Under the microscope, heterochromatin is visible 
within nucleoli as fibrillar centres or as 'knobs' 
arranged around the nucleolar periphery, while 
euchromatin may be present throughout the body of 
the nucleolus. Many lines of evidence support the 
supposition that the compacted heterochromatic 
rDNA is typically inactive, while that which more 
loosely organised is euchromatic and likely to be 
undergoing transcription (Raška et al., 2006). 
Understanding the features of these two chromatin 
states, and the protein complexes which induce 
transitions between them, is thus essential for 
understanding how rRNA transcription is controlled 
(Gerbi et al., 2003). Various reviews describe our 
current understanding of the importance of 
nucleolar organisation and its relationship with 
rDNA packaging, rRNA gene transcription and pre-
rRNA processing in different taxa (Nierras et al., 
1997; Raška et al., 2006; McStay and Grummt, 
2008; Shaw and McKeown, 2011; Shaw and 
Brown, 2012). 
Early evidence on the nature of the molecular 
differences between active and inactive rRNA 
genes was suggested by the chemical manipulation 
of nucleolar dominance by aza-dC and trichostatin 
A, DNA methylation and histone deacetylation 
inhibitors, respectively (Reeder, 1985; Thompson 
and Flavell, 1988; Pikaard, 2000). As these 
pharmacological treatments altered the extent of 
nucleolar dominance, it was concluded that both 
DNA methylation and histone modification might 
differ between rDNA chromatin states in a manner 
related to the control of their transcription (Chen 
and Pikaard, 1997; Pikaard, 1999; McStay, 2006). 
Elucidating the details of what these modifications 
might be has been greatly accelerated by the 
development of the chromatin immunoprecipitation 
(ChIP) technique. For example, it has been shown 
that mammalian rRNA genes can be associated 
with either of two sets of covalent chromatin 
modifications, which correlate with their level of 
transcriptional activity (Santoro et al., 2002). DNA 
of silenced rRNA genes is highly methylated at 
cytosine residues, and is bound by histone octamers 
which are methylated at H3K9 (Figure 1A). Active 
rRNA genes are instead distinguished by DNA 
hypomethylation, and are bound to histone 
octamers incorporating H3K4 marks and 
widespread acetylation of many H3 and H4 lysine 
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residues (Figure 1B). It has also been proposed that 
rDNA can also exist in a third, intermediate state, in 
which the chromatin of the rRNA genes is 
decondensed but they remain transcriptionally 
silent (Figure 1C).  
This is characterised by the simultaneous presence 
of histone modifications associated with 
euchromatin and heterochromatin on different sites 
and may correspond to a 'poised' euchromatic state 
(McKeown and Shaw, 2009; Xie et al., 2012). 
Much research has therefore concentrated on 
determining what roles these chromatin 
modifications play at the molecular level, and to 
what extent they are causal for determining the 
activity of the rRNA genes with which they 
associate. Such studies have made use of many 
different biological systems and have exploited 
genetic, biochemical and cell biological techniques, 
including cell culture models for different human 
cancers and other diseases.  
These studies have demonstrated that while the 
proteins which control rDNA chromatin typically 
vary between different groups of eukaryotic 
organisms, the regulatory networks in which they 
act also have various key features in common. In 
the following section, the control of rDNA 
transcription in humans (and certain model 
systems) will be described. 
rDNA silencing I - control of 
human RNA Pol I transcription by 
protein complexes 
In eukaryote, 45S pre-rRNA is synthesised by a 
dedicated transcriptional system centred on the 
multimeric protein complex, RNA Polymerase I 
(hereafter RNA Pol I). RNA Pol I only catalyzed 
the transcription of rDNA, which is in turn not 
transcribed by any other polymerase system under 
normal conditions. For a general review of the 
biochemical structure of RNA Pol I, see (Vannini, 
2013). In addition to the core subunits of RNA Pol I 
itself, its polymerase activity requires the action of 
several other proteins and protein complexes, many 
of which have regulatory potential.  
These RNA Pol I cofactors and transcription factors 
(TF) allow RNA Pol I to effect transcription at 
active rRNA genes and to determine the level of 
this. 
In humans, the principal RNA Pol I TFs consist of 
the Upstream Binding Factor (UBF), the promoter 
selectivity factor (SL1, (Comai et al., 1992)) and 
the transcription termination factor (TTF-I, 
(Grummt, 2003)). These complexes remain 
associated with rDNA during the cell cycle, even 
during mitosis when rRNA gene transcription is 
silenced but are maintained in an inactivate state 
until transcription resumes in telophase (O'Mahony 
and Rothblum, 1991). Of these proteins, TTF-I is 
essential for activating rDNA transcription as its 
binding initiates an open chromatin conformation 
(Längst et al., 1997; Längst et al., 1998). This open 
chromatin structure is stabilised by the HMG-box 
protein, UBF, which binds ubiquitously across the 
entire rDNA locus (Roussel et al., 1993). The 
importance of UBF for supporting RNA Pol I-
transcription is suggested by the fact that it largely 
supplants the histone octamer-based nucleosome as 
the basic subunit of chromatin at active rRNA 
genes (Zatsepina et al., 1993; O'Sullivan et al., 
2002; Mais et al., 2005). UBF plays a particularly 
critical role at the rRNA gene promoter, where it 
serves as a scaffold for the binding of RNA Pol I 
transcription factors and other processing proteins 
(Mais et al., 2005; Prieto and McStay, 2007). As 
this facilitates RNA Pol I promoter escape (Panov 
et al., 2006), UBF therefore orchestrates the level of 
rRNA transcription at active rRNA genes 
(O'Mahony and Rothblum, 1991; O'Sullivan et al., 
2002; Chen et al., 2004; Sanij et al., 2008). UBF 
activity is itself tightly regulated (Sanij and 
Hannan, 2009), including by post-translational 
modifications, which control how UBF reactivates 
rRNA transcription after it has temporarily ceased 
during mitosis (Voit et al., 1999; Meraner et al., 
2006). Recent work has demonstrated that the 
control of RNA Pol I activity is both necessary and 
sufficient for the formation of the nucleolus in 
human cells (Grob et al., 2014). 
RNA Pol I function also requires a complex termed 
FACT, (facilitates chromatin transcription), which 
can be co-precipitated with RNA Pol I (Birch et al., 
2009). In contrast to UBF which regulates the 
initiation of transcription, FACT is specifically 
required for the efficient passage of polymerases 
through nucleosomes. In this way, FACT facilitates 
transcription by RNA Pol I, II and III and is thus 
essential for transcriptional elongation throughout 
the nucleus (its relationship with other RNA 
polymerases present in plants remains to be 
ascertained). FACT contains two core subunits, 
SSRP1 and Spt16. In accordance with the essential 
nature of FACT for transciption, cells in which 
either subunit is down-regulated display reduced 
transcription at the 3' regions of the rRNA genes 
(Birch et al., 2009). 
Both initiation and elongation can be co-ordinately 
regulated independently of UBF and FACT by 
another large (2-3 MDa) complex, this time 
involved in maintaining an open chromatin 
structure throughout active rDNA repeats. This 
third key complex has been termed B-WICH and its 
core subunits include WSTF, SNF2h and myosin1 
(Percipalle et al., 2006); the complex takes its name 
from the Williams syndrome transcription factor 
(WSTF). B-WICH was first reported to be required 
for efficient transcriptional activity of RNA Pol II.  
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When its subunits are knocked down, the 
abundance of Pol III transcripts is also reduced, 
indicating that its role is not specific for control of 
rDNA activity (Cavellán et al., 2006; Percipalle et 
al., 2006). WSTF is also a component of other 
transcriptional complexes, leading to pleiotropic 
phenotypes when it is disrupted, and most of these 
also includes ncRNA molecules (Cavellán et al., 
2006). The B-WICH complex appears to be 
required for the recruitment of some, but not all, of 
the histone acetyltransferases present at active 
rDNA (Vintermist et al., 2011) which presumably 
explains its mode of action. 
The B-WICH complex physically interacts with the 
Cockayne's syndrome protein (CSB) protein, which 
also has multiple roles in controlling RNA Pol II 
transcription and DNA repair. CSB is itself required 
for RNA Pol I transcription, including performing 
ATP-dependent chromatin remodelling at active 
rDNA repeats (Lebedev et al., 2008).  
CSB can additionally act in an ATP-independent 
manner within another complex, termed CSB 
IP/150. This complex also includes XPG (a protein 
disrupted in certain cases of the human condition, 
Xeroderma Pigmentosum), RNA Pol I itself, and a 
transcription factor complex, TFIIH (Bradsher et 
al., 2002). TFIIH was originally described as a Pol 
II-specific TF, but has subsequently been shown to 
activate Pol I transcription in yeast and mouse as 
well (Iben et al., 2002).  
In human cells, CSB IP/150 performs this 
activation by recruiting a further histone 
acetyltransferase, PCAF, which leads to 
transcriptional initiation at rRNA genes which have 
already adopted an open, poised chromatin state 
(Shen et al., 2013). Curiously, CSB/TFIIH also 
recruits a histone methyltrasferase, G9a, which 
induces H3K9me2, which is generally considered a 
repressive chromatin mark (Yuan et al., 2007). The 
association of CSB with RNA Pol I within CSB 
IP/150 appears to be disrupted by mutations in the 
other components of the complex (Bradsher et al., 
2002). This may be involved in the onset of 
Cockayne Syndrome, a recessive disorder 
associated with premature aging and neural 
degeneration. 
As further evidence of the complexity of RNA Pol I 
transcriptional control, a further such complex has 
been reported from human cells rather recently (in 
2012).  
This time, the complex was associated with the 
establishment of 'poised' or transcription-ready 
rRNA genes and was named 'nucleosome 
remodelling and deacetylation' complex (NuRD) 
(Xie et al., 2012). When cellular growth is 
attenuated and transcription at rDNA reduced, 
NuRD is enriched at rRNA gene promoters which 
are unmethylated, associated with RNA Pol I 
transcription factors, yet kept silent by the 
positioning of a key nucleosome. Notably, this 
complex is also tightly regulated with respect to the 
growth status of the mammalian cells in question, 
via pathways as yet unknown. The trend established 
by UBF and other complexes is that rDNA activity 
is regulated by the activity of multi-protein 
complexes, many with chromatin-modifying 
activities. These complexes, and doubtless more 
which remain to be discovered, are presumed to 
ensure RNA Pol I transcription occurs at an 
appropriate level via multiple, subtle interactions. 
This has been argued to be the main mode of rRNA 
synthesis in mammals under normal circumstances 
(Stefanovsky and Moss, 2006). 
Control of rDNA transcription II - 
the role of silencing complexes 
While UBF determines the activity of RNA Pol I at 
rRNA genes with a suitably open chromatin 
organisation, it is not responsible for determining 
the proportion of rRNA genes which are organised 
in this transcriptionally-permissive manner. In 
human cells, the principal determinant of the ratio 
of active and inactive rRNA genes is the multi-
protein complex NoRC (nucleolar remodelling 
complex) which silences rRNA genes the 
transcriptional of which is not required. NoRC was 
discovered in the 1990s and was initially described 
as a complex of Snf2h/Smarca5 and the large (205 
kDa) DNA-binding protein, Tip5 (transcription 
termination factor 1 (Ttf1)-interacting protein 5) - 
see Figure 2.  
At the sub-cellular level, NoRC was found to 
colocalise at the NORs.  
Since its discovery, it has been established that 
NoRC is essential both for blocking RNA Pol I 
transcription at these inactive rDNA loci, and 
moreover for catalyzing the assembly of rRNA 
genes into a heterochromatic conformation 
(Strohner et al., 2001).  
In other words, it regulates the level of rDNA 
transcription by decreasing the ratio of 
active:inactive rRNA genes, and is therefore 
complementary to the Pol I transcription factors 
which reduce or increase transcription at rRNA 
genes which are already active. NoRC therefore 
seems to play an antagonistic role to complexes 
such as B-WICH and CSB IP/150 (see above), 
although whether these complexes are capable of 
directly regulating NoRC is unclear.  
It has been suggested that complexes associated 
with euchromatic and heterochromatic rDNA might 
be recruited to rDNA at different stages during 
nuclear division, as active and inactive rRNA genes 
undergo replication at different timepoints (Yuan et 
al., 2007).  
The possibility of cross-talk occurring between 
these complexes merits further investigation. 
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Figure 2. Predicted model for the control of rDNA silencing by the Nucleolar Remodelling Complex (NoRC). NoRC 
consists of Tip5 and Snf2h. Tip5 is recruited to rRNA by transcription of a non-coding RNA termed pRNA (bold line). Binding of 
NoRC to rRNA genes leads to TTF-I dependent recruitment of chromatin remodelling enzymes (gray) and repression of rRNA 
transcription. Binding of NoRC to rDNA may require, or be stabilised by, Heterochromatin Protein 1 (HP1) and acetylated H4K16 
residues (not shown). 
 
The key role of NoRC in control of human rDNA 
transcription was first indicated by in vitro 
experiments showing that it was able to induce 
nucleosome sliding (of the sort required for rRNA 
gene silencing) along isolated DNA. This activity 
was dependent upon ATP, and the N-terminal tail 
of histone H4 (Strohner et al., 2001), indicating a 
direct affect upon nucleosome organisation. Based 
on its chromatin-remodelling capabilities and 
colocalisation with UBF in the nucleolus, NoRC 
was therefore recognised as a candidate regulator of 
rDNA transcription control. This hypothesis was 
proven shortly afterwards with the demonstration 
that association of NoRC with rDNA repeats 
caused rRNA genes to become heterochromatic and 
transcriptionally silent (Santoro et al., 2002). The 
biochemical nature of this heterochromatic DNA 
was indicated by the discovery that methylated 
rDNA genes could be immunoprecipitated in 
conjunction with the two components of NoRC 
(Tip5, Snf2). These proteins are additionally co-
immunoprecipitated with hypoacetylated and 
hypermethylated histones, and with 
heterochromatin protein 1 (HP1). This indicated 
again that NoRC was a complex specifically 
associated with methylated, inactive rDNA, and 
that the rRNA genes in this rDNA was likely to be 
organised into heterochromatin. NoRC was 
therefore established as a key element of the 
heterochromatic fraction of rDNA previously 
identified in microscopy-based studies (Santoro et 
al., 2002). 
The study of Santoro et al. furthermore determined 
that the role of NoRC in heterochromatic rDNA 
was likely to be causal rather than correlative. 
Over-expression of Tip5 caused a transfected rDNA 
reporter plasmid to become resistant to cleavage by 
the methylation-sensitive restriction enzyme HpaII, 
indicating that NoRC was able to induce DNA 
methylation in vivo (Santoro et al., 2002). As 
expected, treatment with the DNA methylation 
inhibitor 5-azacytidine reversed this effect (Santoro 
et al., 2002). NoRC is therefore responsible for 
inducing the methylation of rRNA gene promoters 
in mammalian cells. Importantly, the NoRC 
component Tip5 also acts as a binding site for the 
transcription termination factor TTF-I (Németh et 
al., 2004) which had previously been shown to be 
essential for repressive chromatin remodelling at 
the promoter of silenced rRNA genes (Längst et al., 
1997; Längst et al., 1998). It is therefore believed 
that NoRC establishes and maintains the 
heterochromatic organisation of inactive rDNA 
repeats via recruitment of TTF-I and other enzymes 
which induce DNA methylation and the deposition 
of repressive histone modifications.  
These include H3K9 methylation and H4 
hypoacetylation (Santoro et al., 2002) and may be 
mediated by Tip5 binding to H4K16ac via a 
bromodomain, which appears to stimulate 
recruitment of chromatin-remodelling enzymes 
such as HDAC1, DNMT1, DNMT3, and SNF2h to 
the rDNA (Zhou and Grummt, 2005), as shown in 
Figure 2. As an additional level of control, the 
binding of NoRC can be countered by an abundant 
nucleolar protein, nucleolin, which reduces the 
ability of TTF-I to bind to its target terminator 
region and thus reduces Tip5 recruitment (Cong et 
al., 2012). 
Although initially described as a complex of 
proteins, it was subsequently discovered that NoRC 
also contains an essential RNA component. A non-
coding RNA is produced from transcription of the 
rRNA gene promoter, termed pRNA, which binds 
to Tip5 and is required for targeting of the complex 
to the rDNA promoter. pRNA binding mediates 
DNMT3b association with the rRNA gene promoter 
(Bierhoff et al., 2011).  
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Figure 3. The regulation of rRNA gene transcription in response to cellular energy status. The eNOSC complex consists 
of NML (nucleomethylin), SuV (SUV39H1) and SIRT1 (sirtuin 1), and responds to signals indicating low cellular energy status by 
silencing rRNA genes and repressing ribosomal RNA production. At least one other pathway, involving mammalian Target Of 
Rapamycin (mTOR) operates in parallel. For details, and possible interaction of NMP with NMNAT1, see text. 
 
 
pRNA-binding is dependent upon the acetylation of 
Tip5 by an interacting acetyltransferase, MOF 
(Males Absent on the First), which occurs only on 
lysine residue K633 and is essential for the gene-
silencing activity of NoRC (Zhou et al., 2009). The 
pRNA also acts to allow the binding of poly(ADP-
ribose)-polymerase-1 (PARP1) which is essential 
for NoRC to silence RNA Pol I and subsequent 
heterochromatinization of silent rDNA (Guetg et 
al., 2012). 
rDNA silencing III - regulation of 
RNA Pol I silencing by cellular 
energy status 
The manner in which the numerous complexes 
described above interact to control RNA Pol I 
activity remains a difficult issue, but the overall 
purpose of this complexity is clearly to allow rDNA 
activity to be attuned to the environment. One 
cellular condition to which rDNA appears to be 
particularly sensitive is the energetic status of the 
cell, which can (in mammals) regulate rRNA 
transcription by several different signalling 
pathways. This is unsurprising given the high 
demand that rRNA synthesis makes on the cell's 
ATP reserves, sometimes estimated as half of the 
cell's energetic output (Sollner-Webb et al., 1985; 
Grummt and Voit, 2010). Therefore, rDNA 
transcription must occur at a level suitable to meet 
the translational demand of the cell, while also 
taking account of the ATP available in the cell at 
that time. 
The importance of this link, and its wide-ranging 
impacts on the healthy functioning of an organism, 
have been most widely established by studies of the 
budding yeast (Saccharomyces cerevisiae) protein, 
Silent information regulator 2 (Sir2). Sir2 is an 
NAD+-dependent protein deacetylase which is 
sensitive to cellular energy status (Fritze et al., 
1997). Amongst other targets, Sir2 is able to 
deacetylate histones, removing H3-acetyl marks 
associated with open, transcriptionally active 
chromatin and potentially allowing the addition of 
H3-methyl marks, which are associated with 
transcriptionally inactive heterochromatin, Sir2 is 
known to be able to regulate rDNA transcription by 
RNA Pol I, and it has been proposed that this is 
linked to its histone/protein deacetylation 
capabilities (Fritze et al., 1997; Smith et al., 1998; 
Straight et al., 1999; Blander and Guarente, 2004; 
Machín et al., 2004; Ford et al., 2006). The 
ramifications of the role of Sir2 and related proteins 
(the so-called sirtuins) for human health is a topic 
of intense scientific debate, as several lines of 
evidence suggest that Sir2 is a key regulator of 
ageing and longevity in yeast, nematodes and 
metazoans. This may occur through mimicking the 
effects of caloric restriction. It has been claimed, 
for example, that increased cellular dosage of Sir2p 
in S. cerevisiae can expand yeast life span by 
suppressing genotoxic recombination between 
rDNA repeats of the sort discussed below (Lin et 
al., 2000). Here I will focus specifically on the role 
of Sir2 and related proteins in the direct control of 
transcription at the rDNA locus. For the details of 
the ongoing debate over the more controversial 
claims made for these proteins, the reader is 
referred to dedicated commentaries (Finkel et al., 
2009; Lempiäinen and Shore, 2009; Imai and 
Guarente, 2010; Sebastián et al., 2012). 
Sirtuins share the common feature that they use 
NAD+ as a cofactor in the deacetylation of peptide 
targets, which may make them particularly suitable 
as sensors of cellular energy levels. The closest 
human homolog of ScSir2p is SIRTUIN 1 (SIRT1), 
which binds throughout rDNA repeats regardless of 
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their transcriptional state, although the majority of 
it is distributed in other parts of the nucleoplasm 
(Michishita et al., 2005).The importance of the 
links between rDNA transcriptional activity and 
cellular metabolic status was underlined by the 
discovery that SIRT1 is part of a protein complex 
termed eNoSC within human cells (Murayama et 
al., 2008). This complex contains the H3K9me2-
binding protein, Nucleomethylin (NML), SIRT1 
and SUV39H1 (Figure 3). NML had previously 
been shown to be at least partially localised in the 
nucleolus (Andersen et al., 2005) and was identified 
by MS-ChIP to be bound to H3K9me2 at 
transcriptionally inactive rDNA (Murayama et al., 
2008). In vivo over-expression of NML reduced the 
accumulation of nascent rRNA, an effect ablated by 
knock-down of SIRT1 (Murayama et al., 2008). 
The authors of this study proposed a model of 'co-
ordinate binding' of NML and SIRT1 occurring 
specifically at silenced rRNA genes, with SIRT1 
triggering H3K9 hypoacetylation and subsequent 
methylation at the same site. Methylation of 
hypoacetylated H3K9 was found to be at least 
partially due to the methyltransferase activity of 
SUV39H1, which also participates in the same 
complex. This suggests a model in which 
SUV39H1 and SIRT1 compete for modification of 
the same lysine residue. Many aspects of the 
regulation of SIRT1 within eNoSC remain unclear: 
two potentially significant points are that 
nucleomethylin (NML) interacts with a NAD+ 
synthesis enzyme called NMNAT1, which also 
contributes to the silencing of rDNA (Song et al., 
2013) and physically associates with SIRT1 (see 
Figure 3); and that SIRT1 may be able to acetylate 
SUV39H1 in a manner that disrupts their binding. 
As a further complication, there is some evidence 
that NML - which has a methyltransferase-like 
domain - may act via methylation of some 
downstream target (Murayama et al., 2008). 
Although most commonly associated with core 
histones, many other proteins can be subject to 
methylation. eNoSC binding at rDNA is increased 
in HeLa cells under conditions that reduce available 
cellular energy (glucose starvation) and this has 
been found to protect such cells from energy 
deprivation-induced apoptosis. As the discovers of 
eNoSC point out, rDNA-silencing may be critical 
for this although interaction with other apoptosis-
inducing pathways cannot be excluded (Murayama 
et al., 2008). eNoSC does not, however, appear to 
act on, or alter the methylation of, p53. 
Other human sirtuins have different sub-cellular 
distributions, including the cytoplasm and 
mitochondria, while SIRT6 and SIRT7 are also 
nuclear. The only evidence for strong nucleolar 
enrichment was for SIRT7 (Michishita et al., 2005). 
SIRT7 is also of considerable interest for regulation 
of mammalian rDNA as it can also function as an 
activator of RNA Pol I (Ford et al., 2006). Although 
still relatively understudied, it has been shown that 
SIRT7 physically interacts with UBF and remains 
stably associated with both UBF and rDNA during 
mitosis (Grob et al., 2009; Tsai et al., 2012). After 
mitosis, SIRT7 is essential for the resumption of 
rRNA gene transcription during telophase, 
following a phosphorylation-induced conformation 
change performed by an unknown kinase (Grob et 
al., 2009). SIRT7 acts in vivo as an NAD+-
dependent deacetylatase of the transcription-
permissive histone modification H3K18Ac at gene 
promoters, thus reducing transcription (Barber et 
al., 2012). Misregulation of this activity has been 
linked with several aspects of tumour progression 
in human cells and in mice, and a significant 
increase in SIRT7 expression in breast cancer 
samples has been reported (Ashraf et al., 2006; 
Barber et al., 2012). No link between these 
correlations and the control of RNA Pol I has been 
reported, and the control of rDNA by SIRT7 has 
been suggested to be cell- or tissue-specific (Barber 
et al., 2012), although links between rDNA 
misregulation, SIRT7 and oncogenesis could easily 
remain to be discovered. Likewise, the requirement 
for NAD+, which varies in availability with a cell's 
energy status, may represent a significant link 
between to control of rRNA transcription in the 
same way that has been claimed for SIRT1. 
In several eukayotic cells, another energy-sensing 
pathway based around signalling by Target of 
Rapamycin (TOR), which is a major component in 
the nutrient signalling machinery (Figure 3, right 
hand side), has been argued to control to the 
transcription of rRNA (Schmelzle and Hall, 2000; 
Kim et al., 2002). This pathway controls RNA Pol I 
transcription via chromatin remodelling at rDNA 
(Tsang et al., 2003), perhaps directly as TOR itself 
binds to rRNA gene promoters (Tsang et al., 2010). 
In yeast, TOR assists rDNA stability by increasing 
Sir2p association with rDNA (Ha and Huh, 2011) 
and also affects Rrn3p levels (Philippi et al., 2010). 
Whether mammalian TOR (mTOR) is able to 
interact with any of the sirtuins is not currently 
clear (Blagosklonny, 2010). Interestingly, the 
NuRD complex may also be regulated with regard 
to cellular energy status, as ATP is required to 
reverse the associated silencing (Xie et al., 2012). 
Again, the biological significance of this fact 
remains to be fully established. 
The discovery of the presence of these multiple 
complexes poses several intriguing questions. One 
which remains to be resolved is the issue of how the 
different complexes which regulate rDNA function 
in human cell lines interact with one another. 
Another is why such a complex system is required 
to accomplish this regulation. The authors of 
Murayama et al., 2008 suggest an intriguing model 
in which NoRC is required for initiating silencing 
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(following its binding to the transcriptional 
terminator element of rDNA via TTF-I - see 
Strohner et al., 2001) - but it is eNoSC, which 
appears to bind ubiquitously to rDNA throughout 
the nucleolus, that ensures chromatin silencing is 
propagated. This suggests coordinate regulation by 
different complexes might occur, or that different 
complexes might act to reinforce each other's 
activities in order to ensure that regulation of rRNA 
transcription and silencing are both robust and 
responsive. 
Roles for histone modification in 
controlling RNA Pol I 
transcription 
As noted above, the control of rDNA by NoRC is 
initiated when the complex binds to nucleosomes 
containing H4K16ac via a bromodomain in the 
Tip5 protein (Zhou and Grummt, 2005). This leads 
to the subsequent recruitment of multiple histone 
deacetylases and histone methyltransferases which 
induce a heterochromatic organisation at the locus 
and suggests a model in which different histone 
modifications direct various stages of euchromatin 
and heterochromatin formation at the rDNA locus. 
As testament to this, pharmacological inhibition of 
histone-modifying enzymes commonly leads to 
altered rRNA expression levels and nucleolar 
morphology, and changes to nucleolar dominance. 
The association between H4 and NoRC is not the 
only instance in which a major regulatory cascade 
requires binding to histones. H3/H4 dimer was 
identified as a core component of the major S. 
cerevisiae RNA Pol I TF, Upstream Activating 
Factor (UAF) (Keener et al., 1997), in addition to 
four non-histone protein components. Reduction of 
H3 synthesis inhibited rRNA transcription and was 
associated with reduced efficiency of multiple 
processes including initiation/elongation, and rRNA 
processing, although in some cases these were 
indirect effects (Nomura et al., 2004; Tongaonkar et 
al., 2005; Jones et al., 2007). 
In mammalian cells, too, classic biochemical 
studies have shown that the H1 linker histone acts 
as a binding site for the abundant rDNA-associated 
protein, nucleolin (Erard et al., 1988) which is itself 
now known to have nucleosome chaperone activity 
(Angelov et al., 2006). Nucleolin has an affinity for 
unmethylated rRNA gene promoters and appears to 
ensure deposition of H3K4me3 and other histone 
modifications associated with a transcription-
permissive state. On the other hand, nucleolin 
depletion causes H3K9me2 to accumulate (Cong et 
al., 2012). The B-WICH complex also triggers 
altered rDNA activity, this time by recruitment of 
histone acetyltransferases (Vintermist et al., 2011). 
Hence, suitably modified nucleosomes also have  
roles as downstream effectors of chromatin 
regulation at rDNA, acting to reinforce the open 
chromatin structure induced by nucleolin, and 
thereby helping to maintain rRNA transcription at 
active rDNA repeats. As other histone chaperones 
have also been shown to control the activity of 
rDNA in human cells (Kuzuhara and Horikoshi, 
2004) and more recently in Arabidopsis (Li and 
Luan, 2010), histone chaperone activity may have 
more general roles in controlling the balance 
between transcribed and silenced rRNA genes. 
Although covalent modifications at the H3K4 and 
H3K9 residues are well-known regulators of 
transcription and other cellular processes (Iizuka 
and Smith, 2003), additional histone modifications 
may also control rRNA transcription or other 
nucleolar functions, and it is possible that some are 
enriched or specific in the nucleolus (McKeown 
and Shaw, 2009). In mammals, for example, RNA 
Pol I transcription is encouraged via H3K56 
acetylation (Chen et al., 2012), and as noted above 
H3K18 acetylation may be involved in regulation 
of rDNA by SIRT7.  
Active histone demethylation has also been 
implicated in rDNA control: JHDM1B is an 
evolutionarily conserved protein demethylase 
which regulates animal growth and may act as a 
tumour suppressor in mice (see Frescas et al., 2007 
and references therein). JHDM1B binds to human 
rRNA genes in a stable manner reminiscent of 
UBF, and silences rRNA expression via 
demethylation of H3K4me3. This effect has an 
absolute requirement for its JmjC domain and 
appears to be a direct effect as H3K9me2 remains 
unaffected.  
Reduced expression of JHDM1B is associated with 
increased rRNA synthesis and accelerated cell 
growth, and has been reported to occur in brain 
tumour cells (Frescas et al., 2007). 
Epigenetic control of RNA Pol I 
silencing and the importance of 
feedback 
In the preceding sections, some of the protein 
complexes which regulate the silencing of rDNA in 
mammalian and yeast cells have been described. It 
has however been made clear that important details 
about how the different regulatory components 
interact with each other remain to be determined. 
An important conceptual contribution to this 
problem comes from research in plant hybrids, 
which has suggested that epigenetic regulators are 
able to establish 'self-reinforcing loops' at active 
and inactive rRNA genes.  
The details of how these loops are established, and 
their wider relevance, are discussed in the following 
section. 
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Figure 4. The regulation of rRNA gene transcription in the model plant, Arabidopsis thaliana. As in human cells, 
recruitment of rRNA silencing machinery is effected by production of non coding RNA from the rDNA repeats (e.g. 24 nt-siRNAs; 
short black lines); these lead to recruitment of DNA methyltransferases and methyl-binding domain proteins (MDB6, MDB10) and 
histone deacetylases (HDA6) which maintain silencing of rRNA genes by chromatin remodelling. Compared with rRNA gene 
regulation in humans, there is no NoRC, and no role has been reported for the plant ortholog of HP1. 
 
 
In hybrid organisms, it commonly occurs that 
chromatin remodelling of NORs inherited from 
different progenitors ensures that only the rDNA 
inherited from one parent is transcribed while the 
other remains silenced (so-called nucleolar 
dominance). The establishment of active or 
repressed states at the two sets of NORs in 
interspecific hybrids within the Arabidopsis genus 
involves differential DNA methylation reinforced 
by remodelling of the rRNA gene promoter by a 
complex involving the histone deacetylase HDA6, a 
histone deacetylase-like HDT protein, and an 
H3/H4 dimer (Lawrence et al., 2004; Earley et al., 
2006). 
The same loop may also control differences in 
expression between different rRNA genes within 
the same NOR. hda6 mutants show aberrant 
accumulation of rDNA-encoded small RNAs, 
leading to the suggestion that siRNA-triggered 
pathways might also be involved in this chromatin 
remodelling loop as in animals. Furthermore, two 
mutants defective in siRNA biogenesis (dcl3, rdr2) 
disrupt the normal patterns of nucleolar dominance 
when crossed in an inter-specific manner (Preuss et 
al., 2008). The promoters and intergenic spacers of 
the silenced rRNA genes derived from A. thaliana 
were associated with the production of 24nt-
siRNAs from both DNA strands, which were lost if 
DCL3 activity was ablated. In agreement with this, 
nucleolar dominance in Arabidopsis requires Pol IV 
and Pol V (Pontes 2006); exactly how these siRNA 
direct DRM2-mediated methylation, or even if they 
are causative for silencing at all, remains unclear. 
The model proposed by Preuss et al., 2008 was that 
transcription (possibly from promoter-like 
sequences in the intergenic spacers) directs 24-nt 
siRNA production from one of the rRNA alleles 
(Figure 4). 
The demonstration that noncoding RNA (ncRNA) 
is involved in rDNA silencing in Arabidopsis marks 
a point in common between animals and plants, as a 
long ncRNA plays a similar role in mouse (Mayer 
et al., 2006; Mayer et al., 2008). On the other hand, 
no role has been reported for shorter RNA in the 
silencing of inactive rDNA in mammals (as far as is 
known), nor for long ncRNA in plants. A further 
point regarding comparisons between different 
eukaryote taxa is that there is no obvious ortholog 
or even functional analog of Tip5 in Arabidopsis, 
suggesting that there is no direct equivalent of 
NoRC in plants. Physical association with the 
siRNA/epigenetic machinery might be possible 
however - supported by colocalisation within Cajal 
bodies which may lie within the nucleolus (Pontes 
et al., 2006) and could also therefore allow physical 
association with rDNA. Curiously, antisense 
transcription of human rDNA can also occur, this 
time acting to promote H4K20me3, a repressive 
chromatin mark (Bierhoff et al., 2011). It can be 
concluded that effects of non-coding RNA (whether 
siRNAs or lncRNAs) on RNA Pol I transcription 
are likely to be widespread, although the details of 
how they act are likely to vary between species, and 
interact with other regulators in complex ways. 
Nucleolar dominance also depends on an 
Arabidopsis methylcytosine binding domain 
protein, MBD6, being localised to silenced rRNA 
by the de novo DNA methyltransferase DRM2 
(Preuss et al., 2008). This pathway also includes 
other effectors of RNAi (DCL3, RDR2) and leads 
to methylation of the sequence, and subsequent 
binding of MBD6 (Figure 4). This change is 
coincident with association with heterochromatic 
histone marks and DNA condensation, which are 
presumed to ensure that silencing spreads across the 
entire NOR and is maintained in a robust manner. 
This study also demonstrated that mutants and/or 
RNAi knock-downs of genes encoding many other 
DNA methyltransferases, RDR proteins and DCL 
proteins did not affect nucleolar dominance (Preuss 
Mechanisms of rDNA silencing and the Nucleolar Remodelling Complex (NoRC) McKeown PC 
 
 
 
 
 
Atlas Genet Cytogenet Oncol Haematol. 2014; 18(10) 773 
et al., 2008). Therefore, epigenetic regulation of 
rDNA activity is under the control of a particular 
subset of siRNA and chromatin-modifying 
pathways, at least in the A. thaliana X A. arenosa 
system being studied.  
The precise role of MBD6 was not clear at this time 
- when knocked down, it caused siRNA levels to 
increase slightly, suggesting that it might be 
responsible for negative feedback within this loop 
of the system. 
Presumably, the complex pathways which control 
rDNA silencing in Arabidopsis are necessary to 
ensure that its chromatin state - and hence the 
epigenetic regulation of rRNA transcription - is 
stable both temporally and spatially. Its self-
reinforcing nature means that it can act across very 
large genomic regions (many megabases in length), 
and be transmitted with fidelity through nuclear 
divisions, regardless of cell differentiation. It 
should however be added that the actual purpose of 
nucleolar dominance remains unclear, although a 
likely hypothesis is that it prevents the production 
of hybrid ribosomes which might function with 
reduced efficiency. This leads to the important 
conclusion that nucleolar dominance represents a 
modification of endogenous rRNA control, albeit in 
a hybrid background, with many regulatory features 
preserved. However, nucleolar dominance does 
differ in other ways (e.g. the differing requirements 
for de novo DNA methylation (Preuss et al., 2008; 
Earley et al., 2010)), perhaps because it has evolved 
to effect a stable silencing effect, rather than 
allowing environmental response. 
An interesting recent report identified that the 
rRNA genes of Arabidopsis thaliana are not as 
uniform as previously thought.  
Rather, they include at least four variants forms, 
which show distinct features in their regulation 
(Pontvianne et al., 2010).  
The possibility of rRNA gene variants being 
functionally distinct (either under wild-type 
conditions, or following tumourigenesis) would be 
an interesting question to address. In Arabidopsis, it 
has been shown that different H3K9 and K27 
histone methyltransferases are responsible for 
control of expression of these rRNA gene variants 
in A. thaliana and in nucleolar dominance between 
different rDNA from different parents in A. 
thaliana X A. arenosa hybrids (Pontvianne et al., 
2012).  
This again suggests that silencing of rDNA during 
nucleolar dominance is in some respects a guide to 
rDNA control in non-hybrid organisms, and in 
other respects is different. Curiously, mutation of 
certain histone methyltransferases also leads to 
preferential replication of certainly variants 
(Pontvianne et al., 2012), implicating the covalent 
modification of histones in preventing replication 
slippage as well . 
Silencing of aberrant RNA Pol II 
transcription in nucleoli 
A further role for the rDNA silencing pathways 
discussed above came from Saccharomyces 
cerevisiae and concerned the mechanisms which 
ensure that sequences at the rDNA locus are not 
promiscuously transcribed by RNA Pol II. RNA Pol 
I is the most specific of the RNA polymerases 
found in eukaryotes, being solely responsible for 
transcription of rDNA. rDNA transcription is in 
turn specific for RNA Pol I, and is not transcribed 
by RNA Pol II machinery (Grummt, 2003). It has 
been known for some years that this is because of 
chromatin-related pathways which act to prevent 
Pol II transcription from occurring and hence 
ensure polymerase fidelity. Accordingly, if an 
rRNA gene is cloned into a different genomic 
location, then transcription by Pol II can instead 
occur. 
In S. cerevisiae, repression of RNA Pol II 
transcription within the rDNA repeats requires the 
HDAC Sir2p (Smith and Boeke, 1997; Smith et al., 
1998). The repressive activity of Sir2p requires the 
structural chromatin protein, condensin which 
causes rDNA to adopt the correct chromatin 
organisation and is essential for ensuring that 
sufficient Sir2p levels is retained at the rDNA locus 
(Smith et al., 1998; Machín et al., 2004). ScSir2 is a 
component of another rDNA-silencing complex 
which has been termed RENT (regulator of 
nucleolar silencing and telophase exit (Straight et 
al., 1999)) which is anchored to rDNA by the 
component protein Net1 (the name derives from the 
essential role of RENT in coordinating mitotic exit 
and the resumption of rRNA transcription (Cockell 
and Gasser, 1999)). Yeast mutant screens have 
suggested that Set1p is also essential for blocking 
RNA Pol II transcription in the rDNA locus, this 
time acting via deposition of H3K4me3 which in 
this instance is associated with transcriptional 
silencing (Briggs et al., 2001). This activity is 
independent of Sir2, and hence of the RENT 
complex (Bryk et al., 2002), and presumably acts to 
reinforce the repression of RNA Pol II activity. The 
role of histone modifications in preventing RNA 
Pol II transcription at rDNA in mammals is not 
clear, although there is evidence that rDNA 
methylation is required (Gagnon-Kugler et al., 
2009) which indicates that correct chromatin 
organisation is again essential. 
The repression of Pol II-mediated transcription 
from the intergenic spacers of rDNA is another 
important function of HDA6 in Arabidopsis 
thaliana, and an hda6 allele was found to produce 
Pol II-transcribed RNA from cryptic promoters 
throughout the rDNA. This in turn leads to siRNA 
production, which normally causes induction of 
heterochromatin but does not appear to do so in this 
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case (Earley et al., 2010). Instead, the rDNA in 
question was found to be associated with histone 
modifications permissive for transcription such as 
H3K9ac, H3K14ac, H4K16ac. This indicates that 
siRNA production does not necessarily lead to the 
induction of repressive, heterochromatin-forming 
loops (Earley et al., 2010). This lead to the authors 
proposing a model in which HDA6 directly 
regulates Pol I and Pol II transcription, completely 
blocking the latter within the rDNA. In the most 
simple scenario, it could achieve this via 
deacetylation of histones. In this model, DNA 
methylation acts in a reinforcing role, perhaps by 
ensuring that the HDA6 protein remains 
concentrated at rDNA. 
Before concluding this section, it is interesting to 
note that correct chromatin organisation of the 
rDNA repeats may be required not only for 
regulating their transcriptional activity, but also for 
their stability (Peng and Karpen, 2006). This report 
demonstrated that, in Drosophila melanogaster, 
chromatin-regulation pathways (including an RNAi 
pathway involving Dicer-2 and Su(var)3-9, and 
those responsible for dimethylation of H3K9) are 
necessary to prevent the occurrence of inter-repeat 
recombination. This ligase-mediated 
recombination, to which tandemly repeated DNA 
sequences are always prone, has the potential to 
liberate genotoxic circular DNA molecules, which 
were termed extrachromosomal circular repeat 
DNA (eccDNA). This may explain why so many 
pathways have evolved to prevent unregulated Pol 
II to occur at rDNA repeats. How chromatin 
actually prevents inter-repeat recombination 
between repeated DNA sequences is not clear, 
although in human cells an analogous process is 
known to involve the TTF-I complex (Guetg et al., 
2010). Increased copy-number of certain rRNA 
gene variants is observed in histone 
methyltransferase mutants in Arabidopsis, which 
may suggest that correct histone modification also 
contributes to rDNA stability in plants (Pontvianne 
et al., 2012). In mammals, too, recent work has 
suggested that NoRC, or at least one of its 
component proteins, is important for the overall 
chromatin organisation of the rDNA repeats. The 
authors indicate that over-expression of Tip5 causes 
general changes to DNaseI accessibility (Zillner et 
al., 2013), a standard measure of chromatin 
compaction. This need not, however, be a direct 
effect. Given that a similar effect is mimicked by 
serum starvation, it is possible that there the eNoSC 
complex may also influence this process, although 
the direct physical association of Tip5 with the 
nuclear matrix reported here (Zillner et al., 2013) 
could be an additional way of amplifying local 
chromatin remodelling into an rDNA-wide effect. 
As an interesting aside, TTF-I may also have more 
general functions in maintaining heterochromatin 
stability throughout eukaryotic nuclei. Its ability to 
bind and stabilise heterochromatin repeats is for 
example essential for genomic integrity at 
centromeric repeats (Guetg et al., 2010) and 
suggests that its role at rDNA has evolved to 
exploit its chromatin remodelling capabilities. 
Disruption of rDNA silencing and 
cancer prognosis 
Nucleoli have long been observed to exhibit altered 
morphologies in different classes of cancer cell 
(Derenzini et al., 2000; Boisvert et al., 2007; 
Montanaro et al., 2008). In fact, such changes have 
been used as diagnostic and prognostic indicators 
since the early twentieth century (Shiue et al., 
2010). The first report of such a link appears to 
have been by Pianese in 1896 (recorded in Donati et 
al., 2012) and was well-established by the later part 
of the twentieth century (Gani, 1976). This led to 
the hypothesis that there might be a correlation 
between tumourigenesis and the levels of 
rRNA/ribosome synthesis within the cell. At the 
molecular level, it has been noted that at least seven 
proto-oncogenes and/or tumour suppressors can 
alter overall levels of translation (Ruggero and 
Pandolfi, 2003). Furthermore, multiple ribosomal 
proteins are also found to be over-expressed in 
many different tumour types. Correlations between 
elevated rRNA levels and malignant transformation 
have also been observed (Ruggero and Pandolfi, 
2003; White, 2008). This correlation has been 
shown to be consistent in a study of six different 
tumour types, and intriguingly tends to become 
stronger with advancing cancer stage (Williamson 
et al., 2006). rRNA has also been found to be over-
expressed in many prostate cancer cell lines 
(Uemura et al., 2012). 
Such studies provide convincing evidence that the 
changes to nucleolar morphology observed in many 
cancers are likely to be due to increased rRNA 
synthesis within these cells. This also seems to be 
correlated with enhanced translational capacity at 
the ribosome. However, most commentators 
traditionally considered this to be a simple 
consequence of the altered metabolic state of 
tumour cells following the resumption of 
proliferative growth (Donati et al., 2012). In other 
words, the activation level of the rDNA and 
associated nucleolar changes are analogous to the 
effects observed in non-cancerous cells when they 
are actively growing (e.g. in S-phase of the cell 
cycle). As cancer cells typically display elevated 
metabolic rates and hence have greater translational 
requirements compared with non-cancer cells, this 
could potentially explain the correlation between 
altered nucleolar morphology/rDNA transcription 
levels in cancer. Altered nucleolar organisation and 
levels of ribosome components have therefore been 
regarded as useful prognostic markers, but have not 
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been considered from the perspective of cancer 
causation. 
Cancer causation and RNA Pol I 
misregulation 
As described above, RNA Pol I activity is 
associated with rapid cell growth and division 
during cancer, leading to changes to nucleolar 
morphology of potential prognostic use. However, 
some researchers have argued that there may also 
be a causal relationship between misregulation of 
rDNA and the occurrence of cancer (Ruggero and 
Pandolfi, 2003; White, 2008; Montanaro et al., 
2012). In support of this, a recent study by Bywater 
et al. has demonstrated that aberrant hyperactivation 
of Pol I is causally required for malignancy in 
several tumours (see Bywater et al., 2012; 
associated commentary (Hannan et al., 2012)) and 
many oncogenic and tumour-prevention pathways 
upregulate RNA Pol I transcription at rDNA. One 
immediate consequent of this is that RNA Pol I has 
emerged as a potential chemotherapy target. One 
drug which may have important therapeutic 
potential in this regard is quarfloxin, a specific 
RNA Pol I-inhibitor which has been investigated 
for use in the treatment of neuroendocrine 
carcinoma (Drygin et al., 2009). Quarfloxin appears 
to confirm the relationship between altered rRNA 
transcription and prognosis of certain cancer types 
and has also been proposed for use in clinical trials 
for treatment of lymphoma and leukemia. 
If RNA Pol I can be causative for cancer 
progression, this also suggests that there should 
exist cellular mechanisms which regulate rRNA 
transcriptionas a means of tumour prevention. 
rRNA synthesis is generally limited by tumour 
supressors such as p53, ARF, pRB and PTEN via a 
combination of direct and indirect mechanisms 
(Budde and Grummt, 1999; Zhai and Comai, 2000; 
White, 2008; Wang et al., 2013). For example, in 
cell lines derived from gastric cancers which had 
lost expression of the tumour suppressor ZNF545, 
restoration of its expression suppressed cell 
proliferation and induced apoptosis due to 
inhibition of rRNA transcription. Importantly, this 
silencing was linked to restoration of the normal 
heterochromatin marks at the promoters, including 
HP1β binding and H3K4 hypomethylation (Wang 
et al., 2013). Direct regulators of RNA Pol I 
transcription activity act by various mechanisms, 
including promoter remodelling, PIC formation, 
and elevated elongation rates. Such regulators 
include known oncogenes such as AML1-ETO and 
the tumor suppressors p53, pRb, and p14ARF 
(Hannan et al., 2012). Various lines of evidence 
indicate that these pathways often target RNA Pol I 
regulators/TFs such as UBF or RRN3. For example, 
the Retinoblastoma protein is required for 
suppression of UBF (Cavanaugh et al., 1995), 
possibly by preventing SL-1 binding (Hannan et al., 
2000). Studies such as these indicate that rDNA 
misregulation during tumourigenesis, either by 
increased transcription by RNA Pol I at active 
rRNA genes, re-activation of previously silenced 
rRNA genes, or both. 
The human TF complex, c-Myc, is of particular 
interest in the study of eukaryote transcription as it 
is able to regulate RNA Pol I, II and III (Gomez-
Roman et al., 2006). It has therefore been proposed 
to coordinate rDNA transcription with the 
biosynthesis of other ribosome components 
(reviewed (Lempiäinen and Shore, 2009)) i.e. the 
ribosomal proteins (translated from mRNA 
transcribed by RNA Pol II) and the 5S rRNA 
(transcribed by RNA Pol III). The gene encoding c-
Myc is considered a proto-oncogene, which may be 
due to far-reaching effects of c-Myc on 
transcription. In principle, c-Myc could be able to 
single-handedly increase the concentration of 
ribosomes within a cell and so drive growth and 
tumourigenesis (Arabi et al., 2005; Grandori et al., 
2005; van Riggelen et al., 2010). For example, 
rRNA upregulation in prostate cancer lines closely 
correlates with levels c-Myc levels. c-Myc may be 
particularly important for aberrant activity of the 
Pol I complex during tumourigenesis (Uemura et 
al., 2012) although it should be noted that probably 
induces many pleiotropic effects on other cellular 
processes as well. This may make it difficult to 
describe the precise nature of the link and is one 
reason why c-Myc has not been successfully 
targeted by chemotherapy. Identification of some of 
its functional partners may help to resolve these 
complications (Chan et al., 2011). One possible part 
of this network is the kinase ERK, which is able to 
stabilise c-Myc by phosphorylation and can also 
activate both UBF and RRN3 in the same way, 
providing simultaneous routes to rDNA activation 
(Stefanovsky et al., 2001). As a final point, it has 
been reported SIRT7, a potential rRNA gene 
regulator associated with tumour progression (see 
above) may also regulate the expression of 
ribosomal proteins (Barber et al., 2012). It is 
possible that certain other rDNA regulators, 
including sirtuins, might also have be able to alter 
cellular translation in a concerted way reminiscent 
of c-Myc. 
Another route to aberrant rRNA transcription (this 
time independent of c-Myc and ERK) is mediated 
by the growth factor receptor ErbB2, which acts as 
a TF for RNA Pol I. ErbB2 is upregulated in many 
cancers and is associated with increased metastasis 
and other aggressive traits. It appears to act by 
increasing the binding affinity of the polymerase to 
rDNA at transcription sites within the nucleolus, 
identified by visualisation of BrUTP incorporation 
sites (Li et al., 2011). Co-immunoprecipitation 
experiments indicated that ErbB2 binds to RNA Pol 
Mechanisms of rDNA silencing and the Nucleolar Remodelling Complex (NoRC) McKeown PC 
 
 
 
 
 
Atlas Genet Cytogenet Oncol Haematol. 2014; 18(10) 776 
I as part of a complex with β-actin, and this binding 
leads to increased transcription levels in vivo (Li et 
al., 2011). Over-expression of ErbB2 lead to 
increased protein synthesis, indicating that RNA 
Pol I up-regulation can indeed remove the limiting 
factors on total cellular translation. rRNA gene 
silencing can also act to limit tumourigenesis via 
the tumour suppressor ARF, which triggers TTF-I 
nucleolar exit and thus reduced rRNA transcription. 
ARF and one of its target proteins, MDM2 (which 
has E3 ubiquitin ligase activity) compete for 
binding to TTF-I at overlapping sites. When levels 
of ARF are artificially ablated, MDM2 
accumulates, binds to TTF-I at increased levels and 
catalyzes its ubiquitinylation. This reduces the 
concentration of TTF-I in the cell via by targeting it 
for proteosomic degradation (Lessard et al., 2012). 
To understand the cellular networks that are 
proposed to link RNA Pol I regulation to cancer, it 
is also necessary to consider in more detail why 
misregulation might be associated with tumour 
progression, beyond the observation that cancer 
cells have high metabolic requirements. One fact 
which may be critical is the discovery that the key 
oncogene p53, which as noted above may regulate 
RNA Pol I activity, might also be partially 
controlled by it. It has been reported that the 
relative levels of ribosomal RNA (transcribed by 
RNA Pol I) and the rate of ribosomal protein 
synthesis can lead to changes in p53 levels in 
mammalian cells (Donati et al., 2011a). The likely 
complexity of any such interactions is demonstrated 
by research from the same group suggesting that 
Pol I can also control cellular proliferation via a 
p53-independent pathway. This pathway may 
instead involve E2F-1 (Donati et al., 2011b). 
Sensing of reduced cellular energy status in the 
nucleolus by eNoSC has been proposed to play a 
key role in p53 accumulation, eventually leading to 
apoptosis or cell cycle arrest (Kumazawa et al., 
2011). This is argued to occur via reduced rRNA 
synthesis which leads to release of Myb-binding 
protein 1a (MYBBP1A) from the nucleolus. This 
protein catalyzes acetylation of p53, which is a key 
element in causing it to accumulate and function 
(Kumazawa et al., 2011). Conversely, failure to 
down-regulate RNA Pol I could therefore block p53 
hypomethylation as MYBBP1A would remain 
associated with the nucleolus even under pro-
apoptopic conditions. This mechanism provides an 
attractive explanation of how p53-mediated cell 
cycle arrest could rely upon correct transcription of 
rRNA genes, and a route towards therapeutic 
intervention (Donati et al., 2012). It has previously 
been argued that hypoxia-induced acidification of 
human culture cells can promote the binding of 
rDNA to von Hippel-Lindau tumor suppressor 
protein (VHL) which in turn reduces the RNA Pol 
I-activating capacity of UBF (Mekhail et al., 2006). 
This would indicate that hypoxia can directly 
reduce ribosome production via pH-sensitive 
protein-protein interactions as well as via adverse 
affects on cellular energy status and is an additional 
pathway of relevance for disrupted response of the 
RNA Pol I machinery during tumourigenesis. 
The sirtuin HDACs have also been proposed to play 
roles in cancer. HsSIRT1, for example, has been 
implicated in different forms of human cancer 
although determining precisely what role it is 
playing is not always clear (Deng, 2009). It has the 
potential to play a key part in cancer progression 
due to its interactions with p53 and other tumour 
supressors. The regulation of SIRT1 is 
correspondingly complex, as reviewed elsewhere 
(Liu et al., 2009), so its activities - and their 
significance to rDNA silencing - will only be 
briefly summarised here. SIRT1 is able to 
deacetylate p53 and physically interacts in vivo with 
several other proteins which regulate this 
deacetylation ability. Its expression is in turn 
controlled by p53 via two binding sites in its 
promoter, which repress its expression; SIRT1 can 
also repress its own expression via an 
autoregulatory loop as part of a complex with HIC1 
(Chen et al., 2005). A particularly intriguing 
possibility is that SIRT1 might contribute to cancer 
development through a positive feedback loop on c-
MYC expression. It has been proposed that this 
could perpetuate aberrant upregulation of c-MYC 
and suppression of apoptosis during colorectal 
cancer, for example (Menssen et al., 2012). Given 
its many interactions, and the fact that SIRT1 is 
present in in different domains of the nucleus, the 
issue of how these different roles are integrated 
remains an open question. Nor is it clear what role 
its control of rRNA transcription might play in its 
other cellular activities. For a discussion of sirtuin 
inhibitors as candidates for use in chemotherapy see 
(Liu et al., 2009). 
rDNA silencing and further links 
to disease 
A degree of care is needed as even when genes or 
pathways have been implicated in misregulating 
RNA Pol I, it is not necessarily the case that this is 
related to their oncogenic potential. It is likely that 
the significance of altered rDNA silencing may 
vary between cancer types and stages, and may be 
causative in some instances but a downstream 
consequence of malignant transformation in others. 
Such considerations should be borne in mind when 
evaluating the therapeutic potential of altering 
rRNA gene expression in any given case. Many 
chemotherapy agents affect RNA Pol I 
transcription, although of their nature most of these 
affect many other cellular processes as well so how 
critical their effects on the rDNA are remains 
unclear (Drygin et al., 2010). 
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Given what has been said previously concerning the 
potential genotoxic nature of recombination at 
repeated DNA, it is finally possible that mediators 
of rDNA silencing - such as those which control its 
organisation at the chromatin level - may also act as 
oncogenes under some circumstances. For example, 
the risk of rDNA which has deviated from their 
chromatin organisation producing DNA minicircles 
by inter-repeat recombination has been argued to 
have potentially carcinogenic effects (Peng and 
Karpen, 2007).  
The NML-interacting protein NMNAT1 may also 
have roles in preventing DNA breakage, and is 
correlated with increased DNA damage in lung 
cancer (Song et al., 2013), although whether this is 
linked to its role in down-regulating rRNA 
transcription is uncertain. NoRC also plays a role in 
preventing potentially carcinogenic chromosome-
breakage events during nuclear division by 
maintaining cellular heterochromatin (Postepska-
Igielska et al., 2013). However, this has been 
argued to be principally due to its roles in 
stabilising heterochromatin at the centromeres, 
telomeres and associated chromosomal regions, 
rather than at the rDNA locus (Postepska-Igielska 
et al., 2013). On the other hand, general effects on 
genome stability may involve its association with 
rDNA as well as other tandemly repeated regions. 
Although they will not be considered in detail here, 
it should be noted that misregulation of rDNA 
transcription has also been observed various other 
human pathologies, and may be causal in at least 
some cases. These disorders often occur due to 
disruption of the epigenetic pathways which 
regulate RNA Pol I activity and include various 
hypertrophies and atrophies (Hannan et al., 2012). 
Such diseases may share common pathways with 
cancer in that they are typically associated with 
altered cellular growth rates. Defects in components 
of the RNA Pol I machinery itself are also causative 
for a range of rare congenital pathologies 
collectively termed ribosomopathies (Narla and 
Ebert, 2010). 
Summary and conclusion 
Correct regulation of rDNA transcription is a key 
part of the integration between energy status and 
translational capacity. Altered rDNA transcription 
(and associated changes to nucleolar morphology) 
have been correlated with the occurrence of cancer. 
Research over the last twenty years has succeeded 
in identifying some of the key protein complexes 
and chromatin-remodelling pathways which control 
this regulation in humans and in model systems. 
The transcription of rDNA by RNA Pol I can be 
silenced by the activity of NoRC and other 
complexes which form the rRNA genes into a 
repressive chromatin organisation. At active local,  
the exact level of transcription depends upon 
complexes with TF-activity, and especially UBF. 
The interactions between the various complexes 
which can activate or silence rRNA gene 
transcription are still only poorly understood, but it 
is clear that they represent the components of a 
sophisticated regulatory network.  
One key function is to link rRNA production to a 
cell's metabolic requirements and to the its energy 
reserves.  
Perturbation of these regulatory networks is 
therefore detrimental for the cell's function and has 
been linked to various pathologies.  
Elucidation of how misregulation of rDNA 
transcription of this kind contributes to the 
initiation and maintenance of cancer cell growth 
will be the focus of future research initiatives. 
Within this area, a particular question that will need 
to be addressed is the extent to which normalizing 
rRNA gene expression is able to restrict the growth 
of human cell lines and, if so, the nature of the 
molecular mechanisms which regulate this. 
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